The PODNL1/AKT/β-catenin signaling axis mediates glioma progression and sensitivity to temozolomide

•PODNL1 overexpressed in gliomas and significantly associated with clinicopathologic features and molecular subtypes.•PODNL1 overexpression is a biomarker for poor outcome and tumor progression in patients with gliomas.•Overexpression of PODNL1 further promotes the oncogenesis and progression of glioma cells by activating the kinase AKT to induce -catenin nuclear translocation.•The AKT inhibitor MK-2206 significantly increased the sensitivity of glioma cells to temozolomide.